What is Nintedanib?

Category: Prescription Drugs

Most popular types: Ofev IPF Phase III Nintedanib (BIBF1120)

false

Nintedanib is a medication used for the treatment of idiopathic pulmonary fibrosis (IPF). Nintedanib is a kinase inhibitor that blocks multiple pathways that may be involved in the scarring of lung tissue.

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations Percentage
Severe 24
Moderate 41
Mild 73
None 40

Commonly reported side effects and conditions associated with Nintedanib

Side effect Patients Percentage
Diarrhea 80
Nausea 39
Decreased appetite 38
Abdominal pain 34
Indigestion 31
Vomiting 26

Show all 46 reported side effects

Dosages

Based on patients currently taking Nintedanib

Dosage Patients Percentage
150 mg twice daily 25
100 mg twice daily 6
150 mg daily 3
300 mg daily 2

Why patients stopped taking Nintedanib

Multiple reasons could be selected

Reason Patients Percentage
Side effects too severe 20
Doctor's advice 12
Other 7
Did not seem to work 3
Expense 1
See all 32 patients who've stopped taking Nintedanib

Duration

Currently taking Nintedanib

Duration Patients Percentage
1 - 6 months 1
6 months - 1 year 2
1 - 2 years 7
2 - 5 years 23
5 - 10 years 1

Stopped taking Nintedanib

Duration Patients Percentage
Less than 1 month 5
1 - 6 months 17
6 months - 1 year 7
1 - 2 years 1
2 - 5 years 2
Adherence
Adherence Evaluations Percentage
Always 151
Usually 21
Sometimes 0
Never taken as prescribed 6
Burden
Burden Evaluations Percentage
Very hard to take 4
Somewhat hard to take 15
A little hard to take 36
Not at all hard to take 123
Cost per month
Cost per month Evaluations Percentage
$200+ 13
$100-199 1
$50-99 7
$25-49 20
< $25 59
Not specified 78

What people switch to and from

Patients started taking Nintedanib after stopping:

Treatment Patients Percentage
Pirfenidone (Esbriet) 28
Azathioprine (Imuran) 2
Clindamycin (Clindamycin PH 1% Gel) 1
Doxycycline (Doxylin) 1
Fluticasone (Flovent HFA) 1

Show all 9 treatments patients report switching from

Patients stopped taking Nintedanib and switched to:

Treatment Patients Percentage
Pirfenidone (Esbriet) 12
Azathioprine (Imuran) 1
Mycophenolate mofetil (CellCept) 1
Oxygen therapy 1
Last updated:
There are no evaluations for Nintedanib.